Novartis Drug Wins U.S. Approval for Cushing’s Disease
This article is for subscribers only.
Novartis AG’s Signifor won U.S. regulatory approval to treat the rare hormone condition known as Cushing’s disease.
The Food and Drug Administration cleared the drug for patients who can’t be helped with surgery, the agency said yesterday in a statement. The drug lowers excess levels of the hormone cortisol caused by a tumor on the pituitary gland at the base of the brain. Cushing’s disease leads to obesity, skin that bruises easily, excess hair growth in women and decreased sexual desire in men, according to the National Institutes of Health.